Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


25.03.2019

1 Am J Hematol
3 Blood
1 Bone Marrow Transplant
2 Br J Haematol
1 Cancer
2 Haematologica
1 J Biol Chem
4 J Clin Oncol
1 J Immunol
1 Lancet Oncol
1 Leuk Lymphoma
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. STUVER RN, Khan N, Schwartz M, Acosta M, et al
    Single Agents Versus Combination Chemotherapy in Relapsed and Refractory Peripheral T-cell Lymphoma: Results from the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) Registry.
    Am J Hematol. 2019 Mar 21. doi: 10.1002/ajh.25463.
    PubMed     Text format     Abstract available


    Blood


  2. Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132(16):1635-1646.
    Blood. 2019;133:1384-1385.
    PubMed     Text format    

  3. SMITH M, Zakrzewski J, James S, Sadelain M, et al
    Posttransplant chimeric antigen receptor therapy.
    Blood. 2018;131:1045-1052.
    PubMed     Text format     Abstract available

  4. ZAMMARCHI F, Corbett S, Adams L, Tyrer PC, et al
    ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
    Blood. 2018;131:1094-1105.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  5. PREDILETTO I, Farag SA, Bacher U, Jeker B, et al
    High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
    Bone Marrow Transplant. 2019 Mar 19. pii: 10.1038/s41409-019-0508.
    PubMed     Text format    


    Br J Haematol

  6. BLACKLAWS J, Seamone ME, Gupta RR
    Spectral domain optical coherence tomography interpretation.
    Br J Haematol. 2018;181:710.
    PubMed     Text format    

  7. FEND F, Coupland S
    Spectral domain optical coherence tomography interpretation - Response to Blacklaws et al.
    Br J Haematol. 2018;181:711.
    PubMed     Text format    


    Cancer

  8. MOUNIER N, Anthony S, Busson R, Thieblemont C, et al
    Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
    Cancer. 2019 Mar 22. doi: 10.1002/cncr.32040.
    PubMed     Text format     Abstract available


    Haematologica

  9. CASADEI B, Broccoli A, Stefoni V, Pellegrini C, et al
    PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.
    Haematologica. 2019 Mar 19. pii: haematol.2019.215962.
    PubMed     Text format    

  10. BARRANCO GI, Fernandez S, Ona R, Gonzalez-Rincon J, et al
    Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.
    Haematologica. 2019 Mar 19. pii: haematol.2018.214981.
    PubMed     Text format    


    J Biol Chem

  11. CHUNG J, Karkhanis V, Baiocchi RA, Sif S, et al
    Protein Arginine Methyltransferase 5 (PRMT5) Promotes Survival of Lymphoma Cells via Activation of WNT/beta-CATENIN and AKT/GSK3beta Proliferative Signaling.
    J Biol Chem. 2019 Mar 18. pii: RA119.007640. doi: 10.1074/jbc.RA119.007640.
    PubMed     Text format     Abstract available


    J Clin Oncol

  12. YOUNES A, Sehn LH, Johnson P, Zinzani PL, et al
    Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Mar 22:JCO1802403. doi: 10.1200/JCO.18.02403.
    PubMed     Text format     Abstract available

  13. BARR PM
    Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab.
    J Clin Oncol. 2019 Mar 22:JCO1900419. doi: 10.1200/JCO.19.00419.
    PubMed     Text format    

  14. LEONARD JP, Trneny M, Izutsu K, Fowler NH, et al
    AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2019 Mar 21:JCO1900010. doi: 10.1200/JCO.19.00010.
    PubMed     Text format     Abstract available

  15. SHAW AT, Solomon BJ, Besse B, Bauer TM, et al
    ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Mar 20:JCO1802236. doi: 10.1200/JCO.18.02236.
    PubMed     Text format     Abstract available


    J Immunol

  16. PALAZZO A, Herter S, Grosmaire L, Jones R, et al
    The PI3Kdelta-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    J Immunol. 2018;200:2304-2312.
    PubMed     Text format     Abstract available


    Lancet Oncol

  17. GAO Q, Wang XY, Zhou J, Fan J, et al
    Predictive gene-expression score for follicular lymphona.
    Lancet Oncol. 2018;19:e278.
    PubMed     Text format    


    Leuk Lymphoma

  18. ROTOLO A, Karadimitris A, Ruella M
    Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
    Leuk Lymphoma. 2018;59:2040-2055.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  19. BIGI R, Landis JT, An H, Caro-Vegas C, et al
    Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus.
    Proc Natl Acad Sci U S A. 2018;115:E11379-E11387.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: